Afnan to FDA: Simplify Post-Approval Changes, Spur Innovation

21 CFR 314.70, and the process by which FDA reviews changes to already approved applications, needs a risk-based update, now. Consultant Ali Afnan, formerly with FDA, makes his case.

Share Print Related RSS
If you are not automatically redirected, follow this link:
http://www.pharmaqbd.com/afnan_post_approval_changes/

Share Print Reprints Permissions

What are your comments?

You cannot post comments until you have logged in. Login Here.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments